TA-14 pricing is structured around review effort, evidence depth, execution complexity, and implementation scope. Payment never purchases ALLOW, removes a finding, or weakens a governing threshold.
Explore the TA-14 route model, test decision states, and inspect demonstration records before beginning a formal review.
A focused first-pass assessment of whether your route and evidence are structured well enough for meaningful review.
A structured technical review for APIs, agents, workflows, and execution surfaces preparing for admissibility governance.
A deeper analysis of provenance, continuity, completeness, contradiction handling, binding, and preserved artifacts.
A route-level review for systems preparing to govern consequence through the full 24-link execution gate.
For organizations that need sustained route governance, system integration, evidence architecture, and institutional deployment.
Start small when the route is still forming. Move into deeper evidence and runtime review as the system approaches real execution.
| Capability | Sandbox | Reviewability | API Readiness | Evidence Review | Runtime Review |
|---|---|---|---|---|---|
| Public architecture access | ✓ | ✓ | ✓ | ✓ | ✓ |
| Interactive route simulation | ✓ | ✓ | ✓ | ✓ | ✓ |
| Written TA-14 findings | — | ✓ | ✓ | ✓ | ✓ |
| Evidence continuity analysis | — | Initial | Scoped | ✓ | ✓ |
| API and agent boundary mapping | — | — | ✓ | Optional | ✓ |
| 24-link runtime gate mapping | Demo | — | Initial | Optional | ✓ |
| Replay and receipt design | — | — | Initial | Scoped | ✓ |
| Enterprise implementation roadmap | — | — | — | — | ✓ |
TA-14 review fees compensate the work required to examine the route, evidence, authority, continuity, binding, commit, execution, and outcome. The resulting findings remain independent of commercial preference.
Live cumulative activity recorded across the public Exchange surface.
Activity and institutional-state counts only. Registration is not certification. Traffic is not execution evidence. Examination counts establish recorded artifacts, not universal efficacy.